Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy
Authors:
- 5 November 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 58 (3) , 269-276
Abstract
BACKGROUND: To assess whether the expression of p21, p27, and p53 could predict biochemical failure in prostate cancer patients treated with neoadjuvant androgen deprivation prior to salvage radiotherapy for a rising post‐radical prostatectomy (RP) prostate‐specific antigen (PSA).METHODS: The expression of p21, p27, and p53 was determined by immunohistochemistry in a cohort of 74 formalin‐fixed paraffin‐embedded prostate cancer samples obtained from RP. Expression of these markers was then correlated with clinicopathological parameters and biochemical failure‐free survival after salvage radiotherapy.RESULTS: Expression of p21, p27, and p53 was observed in 20%, 69%, and 74% of prostate cancer specimens, respectively. Overexpression of p21 correlated with a higher Gleason score (>7) (P = 0.024). Of the three markers, only p21 expression was correlated with PSA failure after radiotherapy (P = 0.034). In multivariate analysis, both positive p21 (P = 0.004) and pre‐radiation serum PSA > 1 ng/ml (P < 0.0001) were independent predictors of biochemical failure after salvage radiotherapy. Patients with p21− tumors and a serum PSA level ≤ 1 ng/ml before salvage radiotherapy had a biochemical failure‐free survival at 5 years of 83%, compared to 16% at 5 years for those patients with either p21+ tumor or a PSA > 1 ng/ml. Patients with both p21+ and a PSA level > 1 ng/ml had a much lower biochemical failure‐free survival rate of 25% at only 18 months (P < 0.0001).CONCLUSIONS: The expression of p21 in prostatectomy specimens could help predict the likelihood of response to salvage radiotherapy, particularly in patients treated before PSA reaches 1 ng/ml.Keywords
This publication has 24 references indexed in Scilit:
- Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factorsUrology, 2002
- p53 and bcl‐2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomyBJU International, 2002
- Loss of p53 and c-myc Overrepresentation in Stage T2-3N1-3M0 Prostate Cancer are Potential Markers for Cancer ProgressionLaboratory Investigation, 2002
- Radiotherapy for PSA recurrence after radical prostatectomy.European Urology, 2001
- LONG-TERM HAZARD OF PROGRESSION AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: CONTINUED RISK OF BIOCHEMICAL FAILURE AFTER 5 YEARSJournal of Urology, 2000
- RADIOTHERAPY FOR ISOLATED SERUM PROSTATE SPECIFIC ANTIGEN ELEVATION AFTER PROSTATECTOMY FOR PROSTATE CANCERJournal of Urology, 2000
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human CancerAnnual Review of Medicine, 1999
- Transcriptional Regulation of the p21(WAF1/CIP1)GeneExperimental Cell Research, 1999
- Radical Prostatectomy for Stage a Adenocarcinoma of the Prostate: Staging Errors and their Implications for Treatment Recommendations and Disease OutcomeJournal of Urology, 1991